Cablevision Offers On-Screen Caller ID Several cable companies have been experimenting with a feature that will display an incoming caller’s name and number in a little box in the corner of the TV screen.... Read Full Article Alistair Darling’s Confidence Seems Misplaced Despite all the troubles besetting the world economy this year, Britain has nothing much to worry about. That is the official Treasury view, as presented <a href="http://business.time... Read Full Article Author Slips Into Bed With Charles And Di FOR years it was the object of salacious speculation by disreputable tabloids, but the private life of Charles and Diana, the Prince and Princess of Wales, has resurfaced unexpectedly in a very diff... Read Full Article Chinese Calls Prompts CBC To Pull Show A documentary about the Falun Gong spiritual sect was withdrawn by the Canadian Broadcasting Corporation after protests from Chinese diplomats in Canada.... Read Full Article FTSE Hits Seven-year High The FTSE this morning touched its highest point since 2000 and UK blue chips remained buoyant despite fears that Wall Street’s opening would see the Dow Jones give back some of the gains that took i... Read Full Article |
Drug Cuts Recurrence Risk In Breast Cancer PatientsCHICAGO (Reuters) — Taking the breast cancer pill Femara can significantly reduce the chances that a woman’s cancer will return, even long after she has stopped taking the estrogen blocker tamoxifen, American researchers said Monday. The researchers said post-menopausal women who took Femara, manufactured by Novartis, anywhere from one to seven years after finishing a five-year regimen of tamoxifen reduced by 63 percent the risk the cancer would come back. “What our results have shown for the first time in breast cancer treatment history is that taking an anti-estrogen anywhere along that line appears to have a dramatic reduction in the risk of recurrence,” said Dr. Paul Goss of Massachusetts General Hospital, whose study appears in the Journal of Clinical Oncology. The drug, known generically as letrozole, cut the risk of cancer spreading to other areas of the body by 61 percent, and cut the risk that a tumor would develop in the unaffected breast by more than 80 percent. Letrozole belongs to a new class of breast cancer drugs known as aromatase inhibitors, which block the production of estrogen that can lead to cancer. It is recommended for use in women past menopause. The most widely used estrogen-blocking drug is tamoxifen, which was shown to cut the risk of cancer recurrence by close to 50 percent. But benefits of the pill, sold by AstraZeneca under the brand Nolvadex and also sold generically, decrease significantly after five years. Tamoxifen also raises the risk of death from strokes and endometrial cancer. Tag CloudExternal InformationAdditional InformationBattle Against Counterfeit Drugs Has New Weapon: Pollen...Agency Urges Change in Antibiotics for Gonorrhea... Cutting Dosage of Costly Drug Spurs a Debate... A Fight for Life Consumes Both Mother and Son... Where Am I?News Main Page - Business - Drug Cuts Recurrence Risk In Breast Cancer Patients |
i8news.com |